Currently, he is assistant professor in Experimental Medicine at the “Aldo Moro” University of Bari (Italy).
His ongoing research projects focus on the identification of preclinical markers for hereditary colorectal cancers.
She is currently working at her PhD in the Department of Life Sciences of the University of Trieste, and the National Laboratory CIB, in Trieste, Italy, in the laboratory headed by prof. Del Sal.
Her project focus on
- the dissection of the molecular pathways involved in the acquisition of mutant p53 GOF in breast cancer aggressiveness, focused on the mechanism governing chemoresistance and tumor recurrence;
- on the identification of synthetic compounds as potent and specific Pin1 inhibitor for cancer targeted therapy.
He is currently the facility manager for Newcastle University’s Genomics Core in the UK.
He is now working at the Ospedale Civile SS Giovanni e Paolo, in Venice, Italy.
Currently, his scientific interests focus on cognitive errors in medicine, experimental models of gastro-intestinal carcinogenesis, and the role of gastrin in oncology.
After completing her PhD, Simona went on to initiate her residency programme on hematology.
She is currently working as a medical doctor to fulfill her residency program at the Department of Hematology of the Oncology Institute of Southern Switzerland, in Bellinzona.
To date, her research interest has mainly been focused on the oncogenetic role of the human endogenous retrovirus type K (HERV-K) family in human leukemia as well as the colorectal cancer-derived small extracellular vesicles (exosomes) in liver metastasis.
Ting will be supported by a grant from the National Natural Science Foundation Research. Moreover she has gained the Zhengshu Elite Scholarship, under Prof. Shu Zheng’s supervision.
In Rotterdam, she will work at the role played by exosomes in ovarian and colon cancer metastasis.
She is currently working as a surgeon at the Dept. of General and Transplantation Surgery of the University of Heidelberg, Germany. Her research focuses on subgroups of cancer initiating cells as well as neoadjuvant treatment in gastrointestinal carcinomas.
Specific interests include clinical studies in upper GI cancer as well as the identification of markers predictive of response to neoadjuvant therapy and relapse.